

# EVENTITY<sup>®</sup>

## CODING AND BILLING INFORMATION GUIDE



FOR PHYSICIAN OFFICES USING THE CMS 1500



FOR HOSPITALS/INSTITUTIONS USING THE CMS 1450

The information provided in this guide is of a general nature and for informational purposes only. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this guide should in no way be considered a guarantee of coverage or reimbursement for any product or service.

For 340B Entities: Beginning January 1, 2023, Medicare requires that all claims submitted by 340B covered entities on OPPS claims (bill type 13X) for separately payable Part B drugs and biologicals must include modifiers "JG" (Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes) or "TB" (Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes for select entities) on claim lines for drugs acquired through the 340B Drug Discount Program. Additional provider types will be required to use these modifiers in 2024.<sup>1</sup>



AMGEN<sup>®</sup> Support<sup>+</sup>

Call Amgen<sup>®</sup> SupportPlus at 1-866-264-2778 Monday – Friday, 9:00 am – 8:00 pm ET.  
Visit [AmgenSupportPlus.com](https://www.amgen.com/supportplus) to learn how Amgen can help.

### INDICATION

EVENTITY<sup>®</sup> is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The anabolic effect of EVENTITY<sup>®</sup> wanes after 12 monthly doses of therapy. Therefore, the duration of EVENTITY<sup>®</sup> use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered.

### IMPORTANT SAFETY INFORMATION

#### POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENTITY<sup>®</sup> may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENTITY<sup>®</sup> should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENTITY<sup>®</sup> should be discontinued.

**Please see additional Important Safety Information on the back cover.**



**EVENTITY<sup>®</sup>**  
(romosozumab-aqqg)

injection 105 mg/1.17 mL



EVENTITY® (romosozumab-aqqg) Coding Information

Table with 2 columns: Field Name and Value. Fields include Additional Claim Information in Box 19, Coding Information in Box 24D, JW/JZ Modifier, Number of Units in Box 24G, and Considerations.

Administration and Professional Service Coding Information†

Table with 2 columns: Field Name and Value. Fields include Coding Information in Box 24D and Considerations.

Diagnosis Code Information†

Table with 2 columns: Field Name and Value. Fields include ICD-10-CM Code in Box 21 and Coding Information in Box 24D.

- For postmenopausal women with osteoporosis who are diagnosed as intolerant to other available osteoporosis therapies, consult the ICD-10-CM codes.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

†The sample codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for EVENTITY®. Other codes may be more appropriate given internal system guidelines, payer requirements, practice patterns, and the services rendered.

2 Please see Important Safety Information on the back cover.

HEALTH INSURANCE CLAIM FORM (CMS 1500) with annotations for Boxes 19, 21, 23, 24A, and 24D. Includes patient information, insurance details, and procedure codes.

EVENTITY® (romosozumab-aqqg) Coding Information

<b>Revenue Code in Box 42:</b> (Electronic Form: Loop 2400, SV201) <sup>7</sup>	<b>Medicare: 0636</b> , drugs requiring detailed coding. <sup>8</sup> <b>Other Payers: 0250</b> , general pharmacy; OR <b>0636</b> , if required by a given payer. <sup>8,9</sup>
<b>Coding Information in Box 44:</b> (Electronic Form: Loop 2400, SV202-2 [SV202-1=HC/HP]) <sup>7</sup>	<b>HCPCS Code (J-Code): J3111</b> (injection, romosozumab-aqqg, 1 mg) <sup>3</sup>
<b>JW/JZ Modifier</b>	Medicare Part B claims require the use of a JW or JZ modifier for single-dose containers to report discarded or no discarded drug amounts. <b>JW Modifier:</b> Drug amount discarded/not administered to any patient OR <b>JZ Modifier:</b> No discarded amounts Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers. <sup>4,*</sup>
<b>Service Units in Box 46:</b> (Electronic Form: Loop 2400, SV205) <sup>7</sup>	Indicate 210 units for one kit. Each EVENTITY® kit contains one dose, which is 2 injections for a total dose of 210 mg. <sup>5</sup> The NDC number covers both injections. <sup>5</sup>

Administration Coding Information<sup>†</sup>

<b>Revenue Code in Box 42:</b> (Electronic Form: Loop 2400, SV201) <sup>7</sup>	Appropriate revenue code for the cost center in which the service is performed.
<b>Description in Box 43:</b> (Not required by Medicare) <sup>7</sup>	Indicate drug name and unit of measure, for example, EVENTITY® 210 mg.
<b>Coding Information in Box 44:</b> (Electronic Form: Loop 2400, SV202-2 [SV202-1=HC/HP]) <sup>7</sup>	Healthcare providers should consult the payer or Medicare contractor to determine the code most appropriate for administration. It is the provider's responsibility to ensure that codes used are consistent with payer policy and reflect the service performed. <ul style="list-style-type: none"> <li>Determine appropriate product administration CPT code.</li> <li><b>Relevant evaluation and management (E&amp;M) code.</b> Note when an E&amp;M service is billed in addition to other professional services, the following modifier may be required to distinguish it as a separate service: -25 (significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service)</li> </ul>
<b>Considerations:</b>	Each EVENTITY® kit contains one dose, which is 2 injections for a total dose of 210 mg. <sup>3</sup> Applicable codes cover both injections.

Diagnosis/Condition Code Information<sup>†</sup>

<b>Revenue Code:</b>	N/A
<b>ICD-10-CM Code in Box 66:</b> (Electronic Form: Loop 2300, HI01-2 [HI01-1=BK]) <sup>7</sup>	Appropriate ICD-10-CM code(s) for patient condition. Sequencing of codes may vary based on patient's condition and payer's policy. The following primary ICD-10-CM diagnosis code may be appropriate to describe patients <b>with</b> current osteoporotic fracture treated with EVENTITY®: <ul style="list-style-type: none"> <li><b>M80.0</b> _ _ (Age-related osteoporosis with current pathological fracture)<sup>6</sup> <ul style="list-style-type: none"> <li>To ensure specificity, 3 additional characters should follow M80.0 to describe laterality, anatomic site, and encounter type<sup>6</sup></li> </ul> </li> </ul> See page 6 for coding details for patients with current osteoporotic fracture. The following primary ICD-10-CM diagnosis code may be appropriate to describe patients <b>without</b> current osteoporotic fracture treated with EVENTITY®: <ul style="list-style-type: none"> <li><b>M81.0</b> (Age-related osteoporosis without current pathological fracture)<sup>6</sup></li> </ul>

- For postmenopausal women with osteoporosis who are diagnosed as intolerant to other available osteoporosis therapies, consult the ICD-10-CM codes.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

<sup>†</sup>The sample codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for EVENTITY®. Other codes may be more appropriate given internal system guidelines, payer requirements, practice patterns, and the services rendered.



The image shows a CMS 1450 form for Anytown Hospital, 100 Main Street, Anytown, Anystate 01010. The patient is James Smith, 123 Main Street, Anytown, Anystate 12345. The form includes callouts for various boxes:

- (BOX 42) REVENUE CODES:** Enter description for each revenue code. Note: If NDC reporting is required (i.e., for Medicaid and some commercial payers), enter NDC information for EVENTITY® in Box 43. Check with the payer to determine the proper format for NDC reporting.
- (BOX 43) DESCRIPTION:** Indicate the drug name and unit of measure: EVENTITY® 210 mg.
- (BOX 44) PRODUCT AND PROCEDURE CODES:**
  - Product:** Use J3111 (injection, romosozumab-aqqg, 1 mg)
  - JW/JZ Discard Modifier:** JW (discarded units) or JZ (no discarded units) modifier required following HCPCS code with a hyphen (i.e., J3111-JZ) for Medicare Part B claims for drugs in single-use containers.
  - Related Administration Procedure:** Determine appropriate product administration CPT code.
  - Please note:** Each EVENTITY® kit contains one dose, which is 2 injections. Applicable codes cover both injections. Healthcare providers should consult the payer or Medicare contractor to determine which code is most appropriate for administration of EVENTITY®.<sup>3</sup>
- (BOX 46) SERVICE UNITS:** Indicate 210 units for one kit.<sup>3</sup> Each EVENTITY® kit contains one dose, which is 2 injections.
- (BOX 47) TOTAL CHARGES:** Report appropriate charges for product used and related procedures.
- (BOX 66) DIAGNOSIS CODES:** Indicate appropriate ICD diagnosis code as reflected in the patient's medical record. ICD-10 code example: M80.0 (Age-related osteoporosis with current pathological fracture).
- (BOX 80) REMARKS:** If required by the payer, enter additional information such as the NDC.



➤ **M80.0\_\_ \_** (laterality) (anatomic site) (encounter type)\*

Anatomic Site and Laterality	Encounter Type <sup>†</sup>					
	Initial encounter for fracture	Subsequent encounter for fracture with routine healing	Subsequent encounter for fracture with delayed healing	Subsequent encounter for fracture with nonunion	Subsequent encounter for fracture with malunion	Sequela
<b>UNSPECIFIED SITE</b>	M80.00XA	M80.00XD	M80.00XG	M80.00XK	M80.00XP	M80.00XS
<b>SHOULDER</b>						
Right	M80.011A	M80.011D	M80.011G	M80.011K	M80.011P	M80.011S
Left	M80.012A	M80.012D	M80.012G	M80.012K	M80.012P	M80.012S
Unspecified	M80.019A	M80.019D	M80.019G	M80.019K	M80.019P	M80.019S
<b>HUMERUS</b>						
Right	M80.021A	M80.021D	M80.021G	M80.021K	M80.021P	M80.021S
Left	M80.022A	M80.022D	M80.022G	M80.022K	M80.022P	M80.022S
Unspecified	M80.029A	M80.029D	M80.029G	M80.029K	M80.029P	M80.029S
<b>FOREARM</b>						
Right	M80.031A	M80.031D	M80.031G	M80.031K	M80.031P	M80.031S
Left	M80.032A	M80.032D	M80.032G	M80.032K	M80.032P	M80.032S
Unspecified	M80.039A	M80.039D	M80.039G	M80.039K	M80.039P	M80.039S
<b>HAND</b>						
Right	M80.041A	M80.041D	M80.041G	M80.041K	M80.041P	M80.041S
Left	M80.042A	M80.042D	M80.042G	M80.042K	M80.042P	M80.042S
Unspecified	M80.049A	M80.049D	M80.049G	M80.049K	M80.049P	M80.049S
<b>FEMUR<sup>‡</sup></b>						
Right	M80.051A	M80.051D	M80.051G	M80.051K	M80.051P	M80.051S
Left	M80.052A	M80.052D	M80.052G	M80.052K	M80.052P	M80.052S
Unspecified	M80.059A	M80.059D	M80.059G	M80.059K	M80.059P	M80.059S
<b>LOWER LEG</b>						
Right	M80.061A	M80.061D	M80.061G	M80.061K	M80.061P	M80.061S
Left	M80.062A	M80.062D	M80.062G	M80.062K	M80.062P	M80.062S
Unspecified	M80.069A	M80.069D	M80.069G	M80.069K	M80.069P	M80.069S
<b>ANKLE AND FOOT</b>						
Right	M80.071A	M80.071D	M80.071G	M80.071K	M80.071P	M80.071S
Left	M80.072A	M80.072D	M80.072G	M80.072K	M80.072P	M80.072S
Unspecified	M80.079A	M80.079D	M80.079G	M80.079K	M80.079P	M80.079S
<b>PELVIS</b>						
Right	M80.0B1A	M80.0B1D	M80.0B1G	M90.0B1K	M80.0B1P	M80.0B1S
Left	M80.0B2A	M80.0B2D	M80.0B2G	M80.0B2K	M80.0B2P	M80.0B2S
Unspecified	M80.0B9A	M80.0B9D	M80.0B9G	M80.0B9K	M80.0B9P	M80.0B9S
<b>VERTEBRA(E)</b>	M80.08XA	M80.08XD	M80.08XG	M80.08XK	M80.08XP	M80.08XS
<b>OTHER SITE</b>	M80.0AXA	M80.0AXD	M80.0AXG	M80.0AXK	M80.0AXP	M80.0AXS

\*According to the ICD-10-CM Official Guidelines for Coding and Reporting, M80.0 codes are for patients who have a current pathologic fracture at the time of an encounter. The codes under M80 identify the site of the fracture. A code from category M80, not a traumatic fracture code, should be used for any patient with known osteoporosis who suffers a fracture, even if the patient had a minor fall or trauma, if that fall or trauma would not usually break a normal, healthy bone.<sup>8</sup>

<sup>†</sup>According to the ICD-10-CM Official Guidelines for Coding and Reporting, seventh character A is for use as long as the patient is receiving active treatment for the fracture. Assignment of the seventh character is based on whether the patient is undergoing active treatment and not whether the provider is seeing the patient for the first time. Seventh character D is to be used for encounters after the patient has completed active treatment. The other seventh characters, listed under each subcategory in the Tabular List, are to be used for subsequent encounters for treatment of problems associated with healing, such as malunions, nonunions, and sequelae.<sup>8</sup>

<sup>‡</sup>Osteoporotic fracture of femur is the approximate synonym of osteoporotic fracture of the hip.<sup>4</sup>

6 Please see Important Safety Information on the back cover.

CLINICAL DIAGNOSIS DETAILS POTENTIAL ICD-10-CM CODE<sup>4</sup>

- Postmenopausal osteoporosis
- Vertebral fractures
- Encounter for evaluating and continuing treatment for the fractures

Age-related osteoporosis with current pathological fracture

**M80.08XA** ← Initial encounter for fracture

Fracture of vertebrae

CLINICAL DIAGNOSIS DETAILS POTENTIAL ICD-10-CM CODE

- Postmenopausal osteoporosis
- Fracture of left wrist
- Follow-up encounter for routine fracture management (after active treatment has been completed)

Age-related osteoporosis with current pathological fracture

**M80.032D** ← Subsequent encounter for fracture with routine healing

Fracture of forearm Left

\*The diagnosis code examples and the hypothetical scenarios above are informational and should not be a substitute for an independent clinical decision. They are not intended to be directive or a guarantee of reimbursement. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient, is always the responsibility of the provider or physician. Please contact your payer with any questions.

**References:** 1. CMS, Part B Inflation Rebate Guidance: Use of the 340B Modifiers, December 20, 2022, available at <https://www.cms.gov/files/document/part-b-inflation-rebate-guidance340b-modifierfinal.pdf>. Accessed October 31, 2023. 2. Palmetto GBA. ASC 837 v5010 to CMS-1500 Crosswalk. [http://www.palmettogba.com/Palmetto/Providers.Nsf/files/CMS1500\\_837v5010\\_Crosswalk.pdf/\\$File/CMS1500\\_837v5010\\_Crosswalk.pdf](http://www.palmettogba.com/Palmetto/Providers.Nsf/files/CMS1500_837v5010_Crosswalk.pdf/$File/CMS1500_837v5010_Crosswalk.pdf). Accessed October 31, 2023. 3. Centers for Medicare and Medicaid Services. HCPCS Release Code Sets. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Downloads/Other-Codes-2019-July-Revised.zip>. Accessed October 31, 2023. 4. CMS, Discarded Drugs and Biologicals – JW Modifier and JZ Modifier Policy FAQs (January 2023), available at <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>. Accessed October 31, 2023. 5. EVENITY® (romosozumab-aqqg) prescribing information, Amgen. 6. Centers for Medicare and Medicaid Services. ICD-10-CM Tabular List of Diseases and Injuries. <https://www.cms.gov/files/zip/2021-code-tables-tabular-and-index-updated-12162020.zip>. Accessed October 31, 2023. 7. Palmetto GBA. ASC 837I version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk. [http://www.palmettogba.com/Palmetto/Providers.Nsf/files/EDI\\_837I\\_v5010A2\\_crosswalk.pdf/\\$File/EDI\\_837I\\_v5010A2\\_crosswalk.pdf](http://www.palmettogba.com/Palmetto/Providers.Nsf/files/EDI_837I_v5010A2_crosswalk.pdf/$File/EDI_837I_v5010A2_crosswalk.pdf). Accessed October 31, 2023. 8. Value Healthcare Services. Understanding hospital revenue codes. <http://valuehealthcareservices.com/education/understanding-hospital-revenue-codes/>. Accessed October 31, 2023. 9. Centers for Medicare & Medicaid Services. Publication 100-04: Medicare Claims Processing Manual. Chapter 17: drugs and biologicals. Section 80.9: required modifiers for ESAs administered to non-ESRD patients. <http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf>. Accessed October 31, 2023.



## Considerations for Complete Claim Submission

### CORRECT AND COMPLETE PATIENT INFORMATION:

- Patient name
  - ID number
  - Health insurer name and/or group number
- Provider name
  - National provider ID number
  - Contact information

### COLLECT PRODUCT AND BILLING INFORMATION:

- CPT/HCPCS code (J-Code) and units
- Determine appropriate JW or JZ modifier
- Diagnosis code to the highest level of specificity
  - Primary diagnosis code
- Identify appropriate administration code
- Determine prior authorization criteria (if required)
- Medicaid and commercial payers may require NDC reporting

### SUPPLEMENTAL DOCUMENTATION CONSIDERATIONS (INCLUDING TEST RESULTS AND DATE AS APPROPRIATE):

- Original diagnostic T-score and/or FRAX predicted fracture risk
- Previous therapies
  - Reason for discontinuations
- Calcium and Vitamin D
- Prior osteoporosis-related fracture history
  - Location of fracture (provide ICD-10 number[s])
- Referring physician orders
- Risk factors for fracture
- Cardiovascular risk assessment
  - Confirm patients had no myocardial infarction or stroke events within the last 12 months

### CONFIRM BILLING AND PAYER REQUIREMENTS:

- Omit or include punctuation as required in submitted claims
- Follow required time frame for submission after rendering service

## Important Safety Information

### POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENTITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENTITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENTITY® should be discontinued.

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENTITY® compared to those treated with alendronate.

**Contraindications:** EVENTITY® is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENTITY®. EVENTITY® is contraindicated in patients with a history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria.

**Hypersensitivity:** Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENTITY®-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENTITY®.

**Hypocalcemia:** Hypocalcemia has occurred in patients receiving EVENTITY®. Correct hypocalcemia prior to initiating EVENTITY®. Monitor patients for signs and symptoms of hypocalcemia, particularly in patients with severe renal impairment or receiving dialysis. Adequately supplement patients with calcium and vitamin D while on EVENTITY®.

**Osteonecrosis of the Jaw (ONJ):** ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENTITY®. A routine oral exam should be performed by the prescriber prior to initiation of EVENTITY®. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENTITY® should be considered based on benefit-risk assessment.

**Atypical Femoral Fractures:** Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENTITY®. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.

During EVENTITY® treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of EVENTITY® therapy should be considered based on benefit-risk assessment.

**Adverse Reactions:** The most common adverse reactions (≥ 5%) reported with EVENTITY® were arthralgia and headache.

EVENTITY® is a humanized monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.



**Please scan the QR code or visit [www.eventity.com/PI](http://www.eventity.com/PI) for EVENTITY® full Prescribing Information, including Boxed Warning and Medication Guide.**

BUSINESS CARD  
CLEAR SLEEVE

**AMGEN**

One Amgen Center Drive  
Thousand Oaks, CA 91320-1799  
[www.amgen.com](http://www.amgen.com)

© 2023 Amgen Inc. All rights reserved. USA-785-82264 11/23

**AMGEN** Support+

**EVENTITY**<sup>®</sup>  
(romosozumab-aqqg)  
injection 105 mg/1.17 mL

# EVENITY®

## CODING AND BILLING INFORMATION GUIDE



FOR PHYSICIAN OFFICES USING THE CMS 1500



FOR HOSPITALS/INSTITUTIONS USING THE CMS 1450

The information provided in this guide is of a general nature and for informational purposes only. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this guide should in no way be considered a guarantee of coverage or reimbursement for any product or service.

For 340B Entities: Beginning January 1, 2023, Medicare requires that all claims submitted by 340B covered entities on OPPS claims (bill type 13X) for separately payable Part B drugs and biologicals must include modifiers "JG" (Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes) or "TB" (Drug or biological acquired with 340B drug pricing program discount, reported for informational purposes for select entities) on claim lines for drugs acquired through the 340B Drug Discount Program. Additional provider types will be required to use these modifiers in 2024.<sup>1</sup>



**AMGEN** Support<sup>+</sup>

Call Amgen® SupportPlus at 1-866-264-2778 Monday – Friday, 9:00 am – 8:00 pm ET.  
Visit [AmgenSupportPlus.com](https://www.amgen.com/supportplus) to learn how Amgen can help.

### INDICATION

EVENITY® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The anabolic effect of EVENITY® wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY® use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered.

### IMPORTANT SAFETY INFORMATION

#### POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

**Please see Important Safety Information on page 8.**



**EVENITY**®  
(romosozumab-aqqg)

injection 105 mg/1.17 mL



## EVENTITY® (romosozumab-aqqg) Coding Information

<b>Additional Claim Information in Box 19:</b> (Electronic Form: Loop 2300, or 2400, NTE, 02) <sup>2</sup>	EVENTITY® (romosozumab-aqqg), 210 mg
<b>Coding Information in Box 24D:</b> (Electronic Form: Loop 2400, SV1, 01-2) <sup>2</sup>  JW/JZ Modifier	<b>HCPCS code (J-code): J3111</b> (injection, romosozumab-aqqg, 1 mg) <sup>3</sup>  Medicare Part B claims require the use of a JW or JZ modifier for single-dose containers to report discarded or no discarded drug amounts. <b>JW Modifier:</b> Drug amount discarded/not administered to any patient OR <b>JZ Modifier:</b> No discarded amounts  Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers. <sup>4,*</sup>
<b>Number of Units in Box 24G:</b> (Electronic Form: Loop 2400, SV1, 04 [03=UN]) <sup>2</sup>	Indicate 210 units for one kit. Each EVENTITY® kit contains one dose, which is 2 injections for a total dose of 210 mg. <sup>5</sup>  The NDC number covers both injections.

## Administration and Professional Service Coding Information†

<b>Coding Information in Box 24D:</b> (Electronic Form: Loop 2400, SV1, 01-2) <sup>2</sup>	Healthcare providers should consult the payer or Medicare contractor to determine the code most appropriate for administration. It is the provider's responsibility to ensure that codes used are consistent with payer policy and reflect the service performed. <ul style="list-style-type: none"> <li>• Determine appropriate product administration CPT code.</li> <li>• <b>Relevant evaluation and management (E&amp;M) code.</b> Note when an E&amp;M service is billed in addition to other professional services, the following modifier may be required to distinguish it as a separate service: -25 (significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service)</li> </ul>
<b>Considerations:</b>	Each EVENTITY® kit contains one dose, which is 2 injections for a total dose of 210 mg. <sup>5</sup> Applicable codes cover both injections.

## Diagnosis Code Information†

<b>ICD-10-CM Code in Box 21:</b> (Electronic Form: Loop 2300, HI, 01-2) <sup>2</sup>	The following primary ICD-10-CM diagnosis code may be appropriate to describe patients <b>with</b> current osteoporotic fracture treated with EVENTITY®: <ul style="list-style-type: none"> <li>• <b>M80.0__</b> (Age-related osteoporosis with current pathological fracture)<sup>6</sup> <ul style="list-style-type: none"> <li>- To ensure specificity, 3 additional characters should follow M80.0 to describe laterality, anatomic site, and encounter type<sup>6</sup></li> </ul> </li> </ul> See page 6 for coding details for patients with current osteoporotic fracture. The following primary diagnosis code may be appropriate to describe patients <b>without</b> current osteoporotic fracture treated with EVENTITY®: <ul style="list-style-type: none"> <li>• <b>M81.0</b> (Age-related osteoporosis without current pathological fracture)<sup>6</sup></li> </ul> The following secondary diagnosis code may be appropriate to describe patients with a personal history of healed osteoporosis fracture: <ul style="list-style-type: none"> <li>• <b>Z87.310</b> Personal history of healed osteoporosis fracture<sup>6</sup></li> </ul>
-----------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- For postmenopausal women with osteoporosis who are diagnosed as intolerant to other available osteoporosis therapies, consult the ICD-10-CM codes.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

†The sample codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for EVENTITY®. Other codes may be more appropriate given internal system guidelines, payer requirements, practice patterns, and the services rendered.

**Please see Important Safety Information on page 8.**

# Completing the CMS 1500 for Physician Offices



## HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA

PICA

1. MEDICARE  (Medicare#) MEDICAID  (Medicaid#) TRICARE  (ID#/DoD#) CHAMPVA  (Member ID#)  GROUP HEALTH PLAN (ID#) FECA BLK LUNG  (ID#) OTHER  (ID#) 1a. INSURED'S I.D. NUMBER (For Program in Item 1) **XXX-XX-XXXX**

2. PATIENT'S NAME (Last Name, First Name, Middle Initial) **Doe, Jane J** 3. PATIENT'S BIRTH DATE (MM/DD/YY) **07/01/1950** SEX M  F  4. INSURED'S NAME (Last Name, First Name, Middle Initial) **Doe, Jane J**

5. PATIENT'S ADDRESS (No., Street) **1123 Main Street** 6. PATIENT RELATIONSHIP TO INSURED Self  Spouse  Child  Other  7. INSURED'S ADDRESS (No., Street)

CITY **Hometown** STATE **MA** 8. RESERVED FOR NUCC USE CITY STATE

ZIP CODE **01234** TELEPHONE (Include Area Code) **(XXX) XXX-XXXX** ZIP CODE TELEPHONE (Include Area Code)

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial) 10. IS PATIENT'S CONDITION RELATED TO: 11. INSURED'S POLICY GROUP OR FECA NUMBER **11111**

a. OTHER INSURED'S POLICY OR GROUP NUMBER a. EMPLOYMENT? (Current or Previous) YES  NO  b. AUTO ACCIDENT? YES  NO  PLACE (State) c. OTHER ACCIDENT? 11. INSURED'S DATE OF BIRTH (MM/DD/YY) **07/01/1950** SEX M  F

b. RESERVED FOR NUCC USE b. OTHER CLAIM ID (Designated by NUCC) **ABC Employer** c. INSURANCE PLAN NAME OR PROGRAM NAME

c. RESERVED FOR NUCC USE

### (BOX 19) ADDITIONAL CLAIM INFORMATION:

Indicate EVENITY® (romosozumab-aqqg), 210 mg. If required by the payer, enter additional information such as the NDC.<sup>5</sup>

### (BOX 21) DIAGNOSIS OR NATURE OF ILLNESS OR INJURY:

Indicate appropriate ICD diagnosis code as reflected in the patient's medical record. ICD-10 CM code example: M80.0 (Age-related osteoporosis with current pathological fracture).

### (BOX 23) PRIOR AUTHORIZATION NUMBER (IF APPLICABLE)

### (BOX 24G) DAYS OR UNITS:

Indicate 210 units for one kit.<sup>5</sup> Each EVENITY® kit contains one dose, which is 2 injections.

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) **EVENITY® (romosozumab-aqqg), 210 mg**

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind. **M80.0XXXX**

24. A. DATE(S) OF SERVICE From To B. PLACE OF SERVICE C. D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS OR UNITS H. EPST Family Plan I. ID. QUAL. J. RENDERING PROVIDER ID. #

1	01	23	21	01	23	21	11		J3111	XX				XXX:XX	210		NPI
	21	11							96XXX					XXX:XX	1		NPI

### (BOX 24A) SHADED BOX:

If NDC reporting is required (i.e., for Medicaid and some commercial payers), enter NDC for EVENITY® in shaded portion of Item 24A above the date of service. Check with the payer to determine the proper format for NDC reporting.

### (BOX 24D) PROCEDURES, SERVICES, OR SUPPLIES:

#### Product

Use J3111 (injection, romosozumab-aqqg, 1 mg)

#### JW/JZ Discard Modifier

JW (discarded units) or JZ (no discarded units) modifier required in the Modifier box for Medicare Part B claims for drugs in single-use containers (e.g. JZ).

#### Related Administration Procedure

Determine appropriate product administration CPT code.

**Please note:** Each EVENITY® kit contains one dose, which is 2 injections. Applicable codes cover both injections. Healthcare providers should consult the payer or Medicare contractor to determine which code is most appropriate for administration of EVENITY®.<sup>5</sup>

SIGNED **07-01-23** DATE a. **XXXXXXXXXX** b. **XXXXXXXXXX** a. **Hometown, MA 01234** b. **XXXXXXXXXX**

NUCC Instruction Manual available at: [www.nucc.org](http://www.nucc.org)

PLEASE PRINT OR TYPE

APPROVED OMB-0938-1197 FORM 1500 (02-12)

Please see Important Safety Information on page 8.





## EVENTITY® (romosozumab-aqqg) Coding Information

<b>Revenue Code in Box 42:</b> (Electronic Form: Loop 2400, SV201) <sup>7</sup>	<b>Medicare: 0636</b> , drugs requiring detailed coding. <sup>8</sup> <b>Other Payers: 0250</b> , general pharmacy; OR <b>0636</b> , if required by a given payer. <sup>8,9</sup>
<b>Coding Information in Box 44:</b> (Electronic Form: Loop 2400, SV202-2 [SV202-1=HC/HP]) <sup>7</sup>	<b>HCPCS Code (J-Code): J3111</b> (injection, romosozumab-aqqg, 1 mg) <sup>3</sup>
<b>JW/JZ Modifier</b>	Medicare Part B claims require the use of a JW or JZ modifier for single-dose containers to report discarded or no discarded drug amounts. <b>JW Modifier:</b> Drug amount discarded/not administered to any patient OR <b>JZ Modifier:</b> No discarded amounts Effective for dates of service on or after July 1, 2023, Medicare Part B claims require the use of the new JZ modifier for single-use containers when there are no discarded drug amounts. Medicare claims also continue to require the use of the JW modifier (Drug amount discarded/not administered to any patient) for drugs and biologicals that are separately payable under Medicare Part B with discarded amounts from single-dose containers. <sup>4,*</sup>
<b>Service Units in Box 46:</b> (Electronic Form: Loop 2400, SV205) <sup>7</sup>	Indicate 210 units for one kit. Each EVENTITY® kit contains one dose, which is 2 injections for a total dose of 210 mg. <sup>5</sup> The NDC number covers both injections. <sup>5</sup>

## Administration Coding Information<sup>†</sup>

<b>Revenue Code in Box 42:</b> (Electronic Form: Loop 2400, SV201) <sup>7</sup>	Appropriate revenue code for the cost center in which the service is performed.
<b>Description in Box 43:</b> (Not required by Medicare) <sup>7</sup>	Indicate drug name and unit of measure, for example, EVENTITY® 210 mg.
<b>Coding Information in Box 44:</b> (Electronic Form: Loop 2400, SV202-2 [SV202-1=HC/HP]) <sup>7</sup>	Healthcare providers should consult the payer or Medicare contractor to determine the code most appropriate for administration. It is the provider's responsibility to ensure that codes used are consistent with payer policy and reflect the service performed. <ul style="list-style-type: none"> <li>Determine appropriate product administration CPT code.</li> <li><b>Relevant evaluation and management (E&amp;M) code.</b> Note when an E&amp;M service is billed in addition to other professional services, the following modifier may be required to distinguish it as a separate service: -25 (significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service)</li> </ul>
<b>Considerations:</b>	Each EVENTITY® kit contains one dose, which is 2 injections for a total dose of 210 mg. <sup>3</sup> Applicable codes cover both injections.

## Diagnosis/Condition Code Information<sup>†</sup>

<b>Revenue Code:</b>	N/A
<b>ICD-10-CM Code in Box 66:</b> (Electronic Form: Loop 2300, HI01-2 [HI01-1=BK]) <sup>7</sup>	Appropriate ICD-10-CM code(s) for patient condition. Sequencing of codes may vary based on patient's condition and payer's policy. The following primary ICD-10-CM diagnosis code may be appropriate to describe patients <b>with</b> current osteoporotic fracture treated with EVENTITY®: <ul style="list-style-type: none"> <li><b>M80.0</b> __ (Age-related osteoporosis with current pathological fracture)<sup>6</sup> <ul style="list-style-type: none"> <li>To ensure specificity, 3 additional characters should follow M80.0 to describe laterality, anatomic site, and encounter type<sup>6</sup></li> </ul> </li> </ul> See page 6 for coding details for patients with current osteoporotic fracture. The following primary ICD-10-CM diagnosis code may be appropriate to describe patients <b>without</b> current osteoporotic fracture treated with EVENTITY®: <ul style="list-style-type: none"> <li><b>M81.0</b> (Age-related osteoporosis without current pathological fracture)<sup>6</sup></li> </ul>

- For postmenopausal women with osteoporosis who are diagnosed as intolerant to other available osteoporosis therapies, consult the ICD-10-CM codes.

\*Reporting policies for discarded units for payers other than traditional fee-for-service Medicare may vary; providers should check with their specific plans about policies related to billing for discarded drug and use of the JW and JZ modifiers.

<sup>†</sup>The sample codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for EVENTITY®. Other codes may be more appropriate given internal system guidelines, payer requirements, practice patterns, and the services rendered.

**Please see Important Safety Information on page 8.**

# Completing the CMS 1450 Form for Hospitals



1 Anytown Hospital 100 Main Street Anytown, Anystate 01010		2	3a PAT. CNTL. #	4 TYPE OF BILL
8 PATIENT NAME a Smith, James		9 PATIENT ADDRESS a 123 Main Street, Anytown, Anystate 12345		5 FED. TAX NO.
b		c		6 STATEMENT COVERS PERIOD FROM
STAT 18 19		26 27 28		7 THROUGH
OCCURRENCE DATE		29 ACCTD STATE		30
42 REV. CD.		43 DESCRIPTION		44 HCPCS / RATE / HIPPS CODE
1 0636	EVENITY® 210 mg	J3111-XX	45 SERV. DATE	46 SERV. UNITS
2 0510	Clinic	96XXX	MDDYY	210
3			MDDYY	1
				47 TOTAL CHARGES
				XXXXX
				XXXXX
				48 NON-COVERED CHARGES
				49
PAGE ____ OF ____		CREATION DATE		TOTALS
50 PAYER NAME		51 HEALTH PLAN ID	52 REL. INFO	53 ASG. BEN.
A		54 PRIOR PAYMENTS		55 EST. AMOUNT DUE
B		56 NPI		57 OTHER PRV ID
C		60 INSURED'S UNIQUE ID		61 GROUP NAME
A		62 INSURANCE GROUP NO.		
B		64 DOCUMENT CONTROL NUMBER		65 EMPLOYER NAME
C				
66 DX		M80.0XXX		68
69 ADMIT DX		70 PATIENT	71 PPS	72
74		73		
80 REMARKS		81CC a		78 OTHER NPI
EVENITY® (romosozumab-aqqg),		b		QUAL
subcutaneous, 210 mg		c		FIRST
		d		OPERATING NPI
				QUAL
				FIRST
				79 OTHER NPI
				QUAL
				FIRST

**(BOX 42) REVENUE CODES:**  
Enter description for each revenue code. Note: If NDC reporting is required (i.e., for Medicaid and some commercial payers), enter NDC information for EVENITY® in Box 43. Check with the payer to determine the proper format for NDC reporting.

**(BOX 46) SERVICE UNITS:**  
Indicate 210 units for one kit.<sup>3</sup> Each EVENITY® kit contains one dose, which is 2 injections.

**(BOX 47) TOTAL CHARGES:**  
Report appropriate charges for product used and related procedures.

**(BOX 43) DESCRIPTION:**  
Indicate the drug name and unit of measure: EVENITY® 210 mg.

**(BOX 44) PRODUCT AND PROCEDURE CODES:**  
**Product**  
Use J3111 (injection, romosozumab-aqqg, 1 mg)  
**JW/JZ Discard Modifier**  
JW (discarded units) or JZ (no discarded units) modifier required following HCPCS code with a hyphen (i.e., J3111-JZ) for Medicare Part B claims for drugs in single-use containers.  
**Related Administration Procedure**  
Determine appropriate product administration CPT code.  
**Please note:** Each EVENITY® kit contains one dose, which is 2 injections. Applicable codes cover both injections. Healthcare providers should consult the payer or Medicare contractor to determine which code is most appropriate for administration of EVENITY®.<sup>3</sup>

**(BOX 66) DIAGNOSIS CODES:**  
Indicate appropriate ICD diagnosis code as reflected in the patient's medical record. ICD-10 code example: M80.0 (Age-related osteoporosis with current pathological fracture).

**(BOX 80) REMARKS:**  
If required by the payer, enter additional information such as the NDC.



## Age-related osteoporosis with current pathological fracture

➤ **M80.0** \_\_\_ (laterality) (anatomic site) (encounter type)\*

### Encounter Type<sup>†</sup>

Anatomic Site and Laterality	Initial encounter for fracture	Subsequent encounter for fracture with routine healing	Subsequent encounter for fracture with delayed healing	Subsequent encounter for fracture with nonunion	Subsequent encounter for fracture with malunion	Sequela
<b>UNSPECIFIED SITE</b>	M80.00XA	M80.00XD	M80.00XG	M80.00XK	M80.00XP	M80.00XS
<b>SHOULDER</b>						
Right	M80.011A	M80.011D	M80.011G	M80.011K	M80.011P	M80.011S
Left	M80.012A	M80.012D	M80.012G	M80.012K	M80.012P	M80.012S
Unspecified	M80.019A	M80.019D	M80.019G	M80.019K	M80.019P	M80.019S
<b>HUMERUS</b>						
Right	M80.021A	M80.021D	M80.021G	M80.021K	M80.021P	M80.021S
Left	M80.022A	M80.022D	M80.022G	M80.022K	M80.022P	M80.022S
Unspecified	M80.029A	M80.029D	M80.029G	M80.029K	M80.029P	M80.029S
<b>FOREARM</b>						
Right	M80.031A	M80.031D	M80.031G	M80.031K	M80.031P	M80.031S
Left	M80.032A	M80.032D	M80.032G	M80.032K	M80.032P	M80.032S
Unspecified	M80.039A	M80.039D	M80.039G	M80.039K	M80.039P	M80.039S
<b>HAND</b>						
Right	M80.041A	M80.041D	M80.041G	M80.041K	M80.041P	M80.041S
Left	M80.042A	M80.042D	M80.042G	M80.042K	M80.042P	M80.042S
Unspecified	M80.049A	M80.049D	M80.049G	M80.049K	M80.049P	M80.049S
<b>FEMUR<sup>‡</sup></b>						
Right	M80.051A	M80.051D	M80.051G	M80.051K	M80.051P	M80.051S
Left	M80.052A	M80.052D	M80.052G	M80.052K	M80.052P	M80.052S
Unspecified	M80.059A	M80.059D	M80.059G	M80.059K	M80.059P	M80.059S
<b>LOWER LEG</b>						
Right	M80.061A	M80.061D	M80.061G	M80.061K	M80.061P	M80.061S
Left	M80.062A	M80.062D	M80.062G	M80.062K	M80.062P	M80.062S
Unspecified	M80.069A	M80.069D	M80.069G	M80.069K	M80.069P	M80.069S
<b>ANKLE AND FOOT</b>						
Right	M80.071A	M80.071D	M80.071G	M80.071K	M80.071P	M80.071S
Left	M80.072A	M80.072D	M80.072G	M80.072K	M80.072P	M80.072S
Unspecified	M80.079A	M80.079D	M80.079G	M80.079K	M80.079P	M80.079S
<b>PELVIS</b>						
Right	M80.0B1A	M80.0B1D	M80.0B1G	M90.0B1K	M80.0B1P	M80.0B1S
Left	M80.0B2A	M80.0B2D	M80.0B2G	M80.0B2K	M80.0B2P	M80.0B2S
Unspecified	M80.0B9A	M80.0B9D	M80.0B9G	M80.0B9K	M80.0B9P	M80.0B9S
<b>VERTEBRA(E)</b>	M80.08XA	M80.08XD	M80.08XG	M80.08XK	M80.08XP	M80.08XS
<b>OTHER SITE</b>	M80.0AXA	M80.0AXD	M80.0AXG	M80.0AXK	M80.0AXP	M80.0AXS

\*According to the ICD-10-CM Official Guidelines for Coding and Reporting, M80.0 codes are for patients who have a current pathologic fracture at the time of an encounter. The codes under M80 identify the site of the fracture. A code from category M80, not a traumatic fracture code, should be used for any patient with known osteoporosis who suffers a fracture, even if the patient had a minor fall or trauma, if that fall or trauma would not usually break a normal, healthy bone.<sup>8</sup>

<sup>†</sup>According to the ICD-10-CM Official Guidelines for Coding and Reporting, seventh character A is for use as long as the patient is receiving active treatment for the fracture. Assignment of the seventh character is based on whether the patient is undergoing active treatment and not whether the provider is seeing the patient for the first time. Seventh character D is to be used for encounters after the patient has completed active treatment. The other seventh characters, listed under each subcategory in the Tabular List, are to be used for subsequent encounters for treatment of problems associated with healing, such as malunions, nonunions, and sequelae.<sup>8</sup>

<sup>‡</sup>Osteoporotic fracture of femur is the approximate synonym of osteoporotic fracture of the hip.<sup>4</sup>

## Hypothetical Scenarios Illustrating Specificity of M80.0\_\_ ICD-10-CM Codes\*

### CLINICAL DIAGNOSIS DETAILS POTENTIAL ICD-10-CM CODE<sup>4</sup>

- Postmenopausal osteoporosis
- Vertebral fractures
- Encounter for evaluating and continuing treatment for the fractures

Age-related osteoporosis with current pathological fracture

**M80.08XA**

Initial encounter for fracture

Fracture of vertebrae

### CLINICAL DIAGNOSIS DETAILS POTENTIAL ICD-10-CM CODE

- Postmenopausal osteoporosis
- Fracture of left wrist
- Follow-up encounter for routine fracture management (after active treatment has been completed)

Age-related osteoporosis with current pathological fracture

**M80.032D**

Subsequent encounter for fracture with routine healing

Fracture of forearm

Left

\*The diagnosis code examples and the hypothetical scenarios above are informational and should not be a substitute for an independent clinical decision. They are not intended to be directive or a guarantee of reimbursement. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient, is always the responsibility of the provider or physician. Please contact your payer with any questions.

**References:** **1.** CMS, Part B Inflation Rebate Guidance: Use of the 340B Modifiers, December 20, 2022, available at <https://www.cms.gov/files/document/part-b-inflation-rebate-guidance340b-modifierfinal.pdf>. Accessed October 31, 2023. **2.** Palmetto GBA. ASC 837 v5010 to CMS-1500 Crosswalk. [http://www.palmettogba.com/Palmetto/Providers.Nsf/files/CMS1500\\_837v5010\\_Crosswalk.pdf/\\$File/CMS1500\\_837v5010\\_Crosswalk.pdf](http://www.palmettogba.com/Palmetto/Providers.Nsf/files/CMS1500_837v5010_Crosswalk.pdf/$File/CMS1500_837v5010_Crosswalk.pdf). Accessed October 31, 2023. **3.** Centers for Medicare and Medicaid Services. HCPCS Release Code Sets. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Downloads/Other-Codes-2019-July-Revised.zip>. Accessed October 31, 2023. **4.** CMS, Discarded Drugs and Biologicals – JW Modifier and JZ Modifier Policy FAQs (January 2023), available at <https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf>. Accessed October 31, 2023. **5.** EVENITY® (romosozumab-aqqg) prescribing information, Amgen. **6.** Centers for Medicare and Medicaid Services. ICD-10-CM Tabular List of Diseases and Injuries. <https://www.cms.gov/files/zip/2021-code-tables-tabular-and-index-updated-12162020.zip>. Accessed October 31, 2023. **7.** Palmetto GBA. ASC 837I version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk. [http://www.palmettogba.com/Palmetto/Providers.Nsf/files/EDI\\_837I\\_v5010A2\\_crosswalk.pdf/\\$File/EDI\\_837I\\_v5010A2\\_crosswalk.pdf](http://www.palmettogba.com/Palmetto/Providers.Nsf/files/EDI_837I_v5010A2_crosswalk.pdf/$File/EDI_837I_v5010A2_crosswalk.pdf). Accessed October 31, 2023. **8.** Value Healthcare Services. Understanding hospital revenue codes. <http://valuehealthcareservices.com/education/understanding-hospital-revenue-codes/>. Accessed October 31, 2023. **9.** Centers for Medicare & Medicaid Services. Publication 100-04: Medicare Claims Processing Manual. Chapter 17: drugs and biologicals. Section 80.9: required modifiers for ESAs administered to non-ESRD patients. <http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf>. Accessed October 31, 2023.

## Considerations for Complete Claim Submission

### CORRECT AND COMPLETE PATIENT INFORMATION:

- Patient name
  - ID number
  - Health insurer name and/or group number
- Provider name
  - National provider ID number
  - Contact information

### COLLECT PRODUCT AND BILLING INFORMATION:

- CPT/HCPCS code (J-Code) and units
- Determine appropriate JW or JZ modifier
- Diagnosis code to the highest level of specificity
  - Primary diagnosis code
- Identify appropriate administration code
- Determine prior authorization criteria (if required)
- Medicaid and commercial payers may require NDC reporting

### SUPPLEMENTAL DOCUMENTATION CONSIDERATIONS (INCLUDING TEST RESULTS AND DATE AS APPROPRIATE):

- Original diagnostic T-score and/or FRAX predicted fracture risk
- Previous therapies
  - Reason for discontinuations
- Calcium and Vitamin D
- Prior osteoporosis-related fracture history
  - Location of fracture (provide ICD-10 number[s])
- Referring physician orders
- Risk factors for fracture
- Cardiovascular risk assessment
  - Confirm patients had no myocardial infarction or stroke events within the last 12 months

### CONFIRM BILLING AND PAYER REQUIREMENTS:

- Omit or include punctuation as required in submitted claims
- Follow required time frame for submission after rendering service

## Important Safety Information

### POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENTITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENTITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENTITY® should be discontinued.

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENTITY® compared to those treated with alendronate.

**Contraindications:** EVENTITY® is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENTITY®. EVENTITY® is contraindicated in patients with a history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria.

**Hypersensitivity:** Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENTITY®-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENTITY®.

**Hypocalcemia:** Hypocalcemia has occurred in patients receiving EVENTITY®. Correct hypocalcemia prior to initiating EVENTITY®. Monitor patients for signs and symptoms of hypocalcemia, particularly in patients with severe renal impairment or receiving dialysis. Adequately supplement patients with calcium and vitamin D while on EVENTITY®.

**Osteonecrosis of the Jaw (ONJ):** ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENTITY®. A routine oral exam should be performed by the prescriber prior to initiation of EVENTITY®. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENTITY® should be considered based on benefit-risk assessment.

**Atypical Femoral Fractures:** Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENTITY®. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.

During EVENTITY® treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of EVENTITY® therapy should be considered based on benefit-risk assessment.

**Adverse Reactions:** The most common adverse reactions ( $\geq 5\%$ ) reported with EVENTITY® were arthralgia and headache.

EVENTITY® is a humanized monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.

**Please see EVENTITY® full Prescribing Information, including Medication Guide.**

ICD-10 - CM CODE EXAMPLES

**AMGEN**

One Amgen Center Drive  
Thousand Oaks, CA 91320-1799  
www.amgen.com

© 2023 Amgen Inc. All rights reserved. USA-785-82264 11/23

**AMGEN** Support+

  
**EVENTITY**<sup>®</sup>  
(romosozumab-aqqg)  
injection 105 mg/1.17 mL